390 related articles for article (PubMed ID: 21174061)
1. CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non-small cell lung cancer.
Cui F; Wang J; Chen D; Chen YJ
Oncol Rep; 2011 Mar; 25(3):701-8. PubMed ID: 21174061
[TBL] [Abstract][Full Text] [Related]
2. Biologic characteristics of the side population of human small cell lung cancer cell line H446.
Wang B; Yang H; Huang YZ; Yan RH; Liu FJ; Zhang JN
Chin J Cancer; 2010 Mar; 29(3):254-60. PubMed ID: 20193106
[TBL] [Abstract][Full Text] [Related]
3. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
Le H; Zeng F; Xu L; Liu X; Huang Y
Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
[TBL] [Abstract][Full Text] [Related]
4. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties.
Leung EL; Fiscus RR; Tung JW; Tin VP; Cheng LC; Sihoe AD; Fink LM; Ma Y; Wong MP
PLoS One; 2010 Nov; 5(11):e14062. PubMed ID: 21124918
[TBL] [Abstract][Full Text] [Related]
5. Both CD133+ and CD133- subpopulations of A549 and H446 cells contain cancer-initiating cells.
Meng X; Li M; Wang X; Wang Y; Ma D
Cancer Sci; 2009 Jun; 100(6):1040-6. PubMed ID: 19385971
[TBL] [Abstract][Full Text] [Related]
6. CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist.
Sarvi S; Mackinnon AC; Avlonitis N; Bradley M; Rintoul RC; Rassl DM; Wang W; Forbes SJ; Gregory CD; Sethi T
Cancer Res; 2014 Mar; 74(5):1554-65. PubMed ID: 24436149
[TBL] [Abstract][Full Text] [Related]
7. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.
Bertolini G; Roz L; Perego P; Tortoreto M; Fontanella E; Gatti L; Pratesi G; Fabbri A; Andriani F; Tinelli S; Roz E; Caserini R; Lo Vullo S; Camerini T; Mariani L; Delia D; Calabrò E; Pastorino U; Sozzi G
Proc Natl Acad Sci U S A; 2009 Sep; 106(38):16281-6. PubMed ID: 19805294
[TBL] [Abstract][Full Text] [Related]
8. Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy.
Kubo T; Takigawa N; Osawa M; Harada D; Ninomiya T; Ochi N; Ichihara E; Yamane H; Tanimoto M; Kiura K
Cancer Sci; 2013 Jan; 104(1):78-84. PubMed ID: 23066953
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.
Baba T; Convery PA; Matsumura N; Whitaker RS; Kondoh E; Perry T; Huang Z; Bentley RC; Mori S; Fujii S; Marks JR; Berchuck A; Murphy SK
Oncogene; 2009 Jan; 28(2):209-18. PubMed ID: 18836486
[TBL] [Abstract][Full Text] [Related]
10. Differential Expression of Cancer Stem Cell Markers ALDH1 and CD133 in Various Lung Cancer Subtypes.
Roudi R; Korourian A; Shariftabrizi A; Madjd Z
Cancer Invest; 2015; 33(7):294-302. PubMed ID: 26046383
[TBL] [Abstract][Full Text] [Related]
11. The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer.
Horst D; Scheel SK; Liebmann S; Neumann J; Maatz S; Kirchner T; Jung A
J Pathol; 2009 Dec; 219(4):427-34. PubMed ID: 19621338
[TBL] [Abstract][Full Text] [Related]
12. High expression of HIF-2α and its anti-radiotherapy effect in lung cancer stem cells.
Sun JC; He F; Yi W; Wan MH; Li R; Wei X; Wu R; Niu DL
Genet Mol Res; 2015 Dec; 14(4):18110-20. PubMed ID: 26782458
[TBL] [Abstract][Full Text] [Related]
13. Microenvironment-Modulated Metastatic CD133+/CXCR4+/EpCAM- Lung Cancer-Initiating Cells Sustain Tumor Dissemination and Correlate with Poor Prognosis.
Bertolini G; D'Amico L; Moro M; Landoni E; Perego P; Miceli R; Gatti L; Andriani F; Wong D; Caserini R; Tortoreto M; Milione M; Ferracini R; Mariani L; Pastorino U; Roato I; Sozzi G; Roz L
Cancer Res; 2015 Sep; 75(17):3636-49. PubMed ID: 26141860
[TBL] [Abstract][Full Text] [Related]
14. CD133 is a marker of bioenergetic stress in human glioma.
Griguer CE; Oliva CR; Gobin E; Marcorelles P; Benos DJ; Lancaster JR; Gillespie GY
PLoS One; 2008; 3(11):e3655. PubMed ID: 18985161
[TBL] [Abstract][Full Text] [Related]
15. The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer.
Tirino V; Camerlingo R; Franco R; Malanga D; La Rocca A; Viglietto G; Rocco G; Pirozzi G
Eur J Cardiothorac Surg; 2009 Sep; 36(3):446-53. PubMed ID: 19464919
[TBL] [Abstract][Full Text] [Related]
16. Enrichment and characterization of cancer stem cells from a human non-small cell lung cancer cell line.
Zhao C; Setrerrahmane S; Xu H
Oncol Rep; 2015 Oct; 34(4):2126-32. PubMed ID: 26239272
[TBL] [Abstract][Full Text] [Related]
17. Latexin inhibits the proliferation of CD133+ miapaca-2 pancreatic cancer stem-like cells.
Xue ZX; Zheng JH; Zheng ZQ; Cai JL; Ye XH; Wang C; Sun WJ; Zhou X; Lu MD; Li PH; Cai ZZ
World J Surg Oncol; 2014 Dec; 12():404. PubMed ID: 25551472
[TBL] [Abstract][Full Text] [Related]
18. Expression of CD133 in synovial sarcoma.
Terry J; Nielsen T
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):159-65. PubMed ID: 19752721
[TBL] [Abstract][Full Text] [Related]
19. [Sorting of CD133(+) subset cells in human gastric cancer and the identification of their tumor initiating cell-like properties].
Lu RQ; Wu JG; Zhou GC; Jiang HG; Yu JW; Jiang BJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Feb; 15(2):174-9. PubMed ID: 22368028
[TBL] [Abstract][Full Text] [Related]
20. CD133 and CD44 cell surface markers do not identify cancer stem cells in primary human gastric tumors.
Rocco A; Liguori E; Pirozzi G; Tirino V; Compare D; Franco R; Tatangelo F; Palaia R; D'Armiento FP; Pollastrone G; Affuso A; Bottazzi EC; Masone S; Persico G; Nardone G
J Cell Physiol; 2012 Jun; 227(6):2686-93. PubMed ID: 21898409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]